Home Newsfeeds Morgan Stanley Downgrades SEI Investments to Underweight

Morgan Stanley Downgrades SEI Investments to Underweight

Morgan Stanley analyst Ryan Kenny downgrades SEI Investments (NASDAQ:SEIC) from Equal-Weight to Underweight.

byBenzinga Newsdesk

July 12, 2022

1 minute read

Morgan Stanley analyst Ryan Kenny downgrades SEI Investments (NASDAQ:SEIC) from Equal-Weight to Underweight.

Trader Who Turned $15K Into $5M Predicts These 4 Meme Coins To Emulate The Success Of DOGE, SHIB, FLOKI

By Khyathi Dalal

April 26, 6:16 AM

As the “meme coin supercycle” chugs on, several traders have chipped in with lofty price predictions about which meme coins could net traders massive gains.

$DOGE

Craig-Hallum Maintains Buy on Sanmina, Raises Price Target to $70

By Benzinga Newsdesk

August 2, 9:47 AM

Craig-Hallum analyst Christian Schwab maintains Sanmina (NASDAQ:SANM) with a Buy and raises the price target from $65 to $70.

SANM

Bitcoin Experts Say Price Plunge To $39,000 Is ‘Healthy For The Market’: Here’s Why

By Murtuza Merchant

January 23, 10:44 AM

Bitcoin's (CRYPTO: BTC) plunge below the $39,000 mark signifies a downturn in market value.

BTC

Annovis Bio Receives Positive Recommendation To Continue Phase 2/3 Trial Of Buntanetap For Alzheimer’s Disease Patients From The Independent Data And Safety Monitoring Board

By Benzinga Newsdesk

October 30, 4:46 PM

Annovis Bio, Inc. (NYSE:ANVS), announces the positive safety review by the Data and Safety Monitoring Board (DSMB) for its phase 2/3 trial of buntanetap, a drug candidate for moderate to mild Alzheimer's Disease (AD)

ANVS

Morgan Stanley Downgrades SEI Investments to Underweight

Related Posts

Trader Who Turned $15K Into $5M Predicts These 4 Meme Coins To Emulate The Success Of DOGE, SHIB, FLOKI

Craig-Hallum Maintains Buy on Sanmina, Raises Price Target to $70

Bitcoin Experts Say Price Plunge To $39,000 Is ‘Healthy For The Market’: Here’s Why

Annovis Bio Receives Positive Recommendation To Continue Phase 2/3 Trial Of Buntanetap For Alzheimer’s Disease Patients From The Independent Data And Safety Monitoring Board